And what it will not. Professional Opin Pharmacother 2012, 13(11):1599613. 28. Voruganti L, Awad G:

And what it will not. Professional Opin Pharmacother 2012, 13(11):1599613. 28. Voruganti L, Awad G: Personal evaluation of transitions in remedy (PETIT) a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophren Res 2002, 56:376. 29. Ware JE, Kosinski M, Keller SD: A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Medical Care 1996, 34(three):22033. 30. Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, Peng X, Conley RR: The cost of relapse along with the predictors of relapse within the treatment of schizophrenia. BMC Psychiatry 2010, 10:2. 31. Stahl SM: From antipsychotic agents. In Antipsychotics and Mood Stabilizers: Stahl’s Important Psychopharmacology. 3rd edition. New York: Cambridge University Press; 2008:18586. 32. Awad AG: Subjective tolerability of antipsychotic medications and also the emerging science of subjective tolerability problems. Expert Rev Pharmacoeconomics Outcomes Res 2010, 10(1):1. 33. Voruganti L, Cortese L, Oyewumi L, Cernovsky A, Zirul S, Awad A: Comparative evaluation of traditional and novel antipsychotic drugs with reference to their subjective tolerability side-effect profile and effect on high quality of life. Schizophr Res 2000, 43(two):13545. 34. Papaioannou D, Brazier J, Parry G: How valid and responsive are generic overall health status measures, like EQ-5D and SF-36, in schizophrenia A systematic critique. Value Overall health 2011, 14(six):9070.35. Ganesan S, Agambaram V, Randeree F, Eggens I, Huizar K, IL-2 Inhibitor Formulation Meuliend D: Switching from other antipsychotics to once-daily extended release quetiapine fumarate in individuals with schizophrenia. Curr Med Res Opin 2008, 24(1):212. 36. Kim S-W, Shin I-S, Kim J-M, Lee J-H, Lee Y-H, Yang S-J, Yoon J-S: Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia. Clin Neuropharmacol 2009, 32(5):24349. 37. Weiden PJ, Simpson GM, Potkin SG, O’Sullivan RL: Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry 2003, 64(5):58088. 38. Kim S-W, Shin I-S, Kim J-M, Lee S-H, Lee Y-H, Yang S-J, Yoon J-S: Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive functioning in individuals with schizophrenia. Hum Psychopharmacol Clin Exp 2009, 24:56573. 39. Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ: Clinical and financial ramifications of switching antipsychotics in the remedy of schizophrenia. BMC Psych 2009, 9:54. 40. Casey DE, Carson WH, Saha AR, Liebeskind A, Ali MW, Jody D, Ingenito GG, Aripiprazole study group: Switching sufferers to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacol (Berl) 2003, 166(four):391. 41. Su J, Barr AM, Procyshyn RM: Adverse events linked with switching from conventional antipsychotic drugs or risperidone to olanzapine. J Psychiatry Neurosci 2012, 37(1):E1 2.doi:ten.1186/1471-244X-14-53 Cite this short article as: Awad et al.: Health-related high-quality of life among patients treated with lurasidone: final results from a switch trial in sufferers with schizophrenia. BMC Psychiatry 2014 14:53.Submit your next manuscript to BioMed Central and take complete benefit of:Easy on the net ERβ Modulator manufacturer submission Thorough peer evaluation No space constraints or color figure charges Instant publication on acceptance Inclusion in PubMed, CAS, Scopus and Google Scholar Study that is freely accessible for redistributionSubmit you.